Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Friedlander

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Chinese Clinical Oncology|April 6, 2015
Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)Michael L Friedlander
Cancer|January 23, 2020
Do all patients with recurrent ovarian cancer need systemic therapy?Michael L Friedlander
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?Kelly-Anne Phillips, Michael L Friedlander
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 31, 2025
Erratum to 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668]Michael L Friedlander, Lyndal Anderson, Yeh Chen Lee
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 21, 2025
Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumorsMichael L Friedlander, Lyndal Anderson, Yeh Chen Lee
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2011
The role of hormonal therapy in gynecological cancers-current status and future directionsKatrin M Sjoquist, Julie Martyn, Richard J Edmondson, et al.
The Oncologist|November 10, 2017
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to ImproveMichelle K Wilson, Michael L Friedlander, Florence Joly, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 5, 2021
Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the EvidenceCiara Conduit, Roger L Milne, Michael L Friedlander, et al.
Breast (Edinburgh, Scotland)|October 1, 2015
Dry eyes and AIs: If you don't ask you won't find outHolly Inglis, Frances M Boyle, Michael L Friedlander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 4, 2016
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical TrialsMichael L Friedlander, Kenneth Russell, Sherri Millis, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Chinese Clinical Oncology|April 6, 2015
Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)Michael L Friedlander
Cancer|January 23, 2020
Do all patients with recurrent ovarian cancer need systemic therapy?Michael L Friedlander
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?Kelly-Anne Phillips, Michael L Friedlander
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 31, 2025
Erratum to 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668]Michael L Friedlander, Lyndal Anderson, Yeh Chen Lee
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 21, 2025
Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumorsMichael L Friedlander, Lyndal Anderson, Yeh Chen Lee
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2011
The role of hormonal therapy in gynecological cancers-current status and future directionsKatrin M Sjoquist, Julie Martyn, Richard J Edmondson, et al.
The Oncologist|November 10, 2017
A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to ImproveMichelle K Wilson, Michael L Friedlander, Florence Joly, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 5, 2021
Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the EvidenceCiara Conduit, Roger L Milne, Michael L Friedlander, et al.
Breast (Edinburgh, Scotland)|October 1, 2015
Dry eyes and AIs: If you don't ask you won't find outHolly Inglis, Frances M Boyle, Michael L Friedlander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 4, 2016
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical TrialsMichael L Friedlander, Kenneth Russell, Sherri Millis, et al.
Pageof 9